DPP-4 inhibitor-related pemphigoid

Excerpt

Appropriate measures should be taken if patients develop pemphigoid caused by dipeptidyl peptidase-1 (DPP-4) inhibitors (alogliptin, linagliptin, sitagliptin and saxagliptin), advises the Japanese Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency (PMDA) in safety advice published in the WHO Pharmaceuticals Newsletter .Although Japanese package inserts for DPP-4 inhibitors include a precaution for pemphigoid, cases have been reported in whom DPP-4 inhibitor-related pemphigoid was exacerbated and resulted in hospitalisation because treatment was continued despite skin abnormalities being observed.The MHLW and PMDA advise healthcare professionals that if patients develop oedematous erythema with itching, blisters and erosion during treatment with DPP-4 inhibitors, and pemphigoid is suspected, et al. dermatologist should be consulted immediately and appropriate measures should be taken including discontinuation of the DDP-4 inhibitor treatment. …